Senzime reports net sales of SEK 25,7 million for the second quarter of 2025, an increase of 72 percent. Currency-adjusted sales increased by 88 percent. The company delivered 727 TetraGraphsystems during the quarter and has now delivered over 4 systems in total. EBITDA improved to SEK -100 million (-23,6). A directed share issue of SEK 28,9 million was carried out during the quarter. CEO Philip Siberg comments that momentum is holding up with record sales and more secured hospital contracts.
|
Published July 18, 2025
Senzime reports 72 percent growth
Notes
Galecto acquires Damora Therapeutics
Cereno Scientific submits protocol for Phase IIb study to FDA
Camurus shows promising results for monthly semaglutide depot
Lytix Biopharma presents new phase II data for ruxotemitide
Ascendis Pharma reports long-term positive results for the treatment of hypoparathyroidism
Xintela carries out rights issue of SEK 72,8 million
Sobi shows strong Phase III results for olezarsen in severe hypertriglyceridemia
NEWSLETTER
Upcoming events
Life Science Summit
The Nordic region's leading forum for early-stage and growth-phase life science companies. The Summit bridges innovation and capital by providing...
MedTech Summit 2026
A new, much-needed MedTech forum in one of Europe's leading life science clusters. As the first event of its kind...
Recommended
Pila Pharma stands out in next-generation obesity pipeline
Novo Nordisk challenges Pfizer in billion-dollar battle for Metsera
New major investment will strengthen Europe's life science sector
The pharmaceutical sector is riding a USD 61,6 billion R&D wave
SwedenBIO wants to give growth power to the industry
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account
Today's news roundup
